PHBI 8-K
Pharmagreen Biotech Inc. (PHBI)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 22, 2020
Pharmagreen Biotech Inc. |
(Exact name of registrant as specified in its charter) |
Nevada |
| 333-151350 |
| 26-1679929 |
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
2987 Blackbear Court, Coquitlam, British Columbia, V3E 3A2
(Address of Principal Executive Offices) (Zip Code)
702-803-9404
(Registrant's telephone number, including area code)
_______________________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Shares | PHBI | OTC Markets |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
ITEM 1.01 Entry into a Material Definitive Agreement
Corporate Notes Listing Services Agreement
Effective July 9, 2020, the Company entered into a consulting agreement with Milestone Management Services (“Consultant”). Pursuant to the terms of the agreement, the Consultant will advise the Company’s management regarding current and potential projects, acquisitions, sales, mergers and other day to day decision making questions.
The term of the consulting agreement is thirty (30) days, terminating on August 10, 2020.
The description of the transaction contemplated by this agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the documents filed as exhibits hereto and incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized.
| Pharmagreen Biotech Inc. |
| |
|
|
|
|
Dated: July 20, 2020 | By: | /s/ Peter Wojcik |
|
|
| Peter Wojcik |
|
|
| Chief Executive Officer, Director |
|
